Could a pill help patients breathe easier with ARDS?
NCT ID NCT07086755
First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This study tests a drug called vadadustat in 1,100 hospitalized adults with acute respiratory distress syndrome (ARDS) caused by infection. Participants take either a low or high dose of vadadustat or a placebo daily for up to 14 days. The goal is to see if the drug reduces deaths and the need for breathing support like ventilators.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vadadustat (oral tablet)
- What this could lead to
- If it works, this could provide a new treatment to reduce deaths and shorten the need for breathing machines in patients with severe lung injury.
- What could go wrong
- This is an early-to-mid stage trial, so results may not confirm benefit. The drug may cause side effects or not improve outcomes compared to placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONINTUBATED ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas Health Science Center at Houston
RECRUITINGHouston, Texas, 77030, United States